These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25501463)

  • 21. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician adherence to ACR gout treatment guidelines: perception versus practice.
    Oderda GM; Shiozawa A; Walsh M; Hess K; Brixner DI; Feehan M; Akhras K
    Postgrad Med; 2014 May; 126(3):257-67. PubMed ID: 24918810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Better outcomes for patients with gout.
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S
    Inflammopharmacology; 2020 Oct; 28(5):1395-1400. PubMed ID: 32095979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL; Macdonald PA; Hunt B; Jackson RL
    Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
    Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
    Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma oxypurinol as a measure of adherence in clinical trials.
    Stamp LK; Merriman T; Frampton C; Zhang M; Wallace M; Miner JN; Dalbeth N
    Ann Rheum Dis; 2018 Feb; 77(2):313-314. PubMed ID: 28057666
    [No Abstract]   [Full Text] [Related]  

  • 32. Adherence with urate-lowering therapies for the treatment of gout.
    Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
    Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient perspectives in gout: a review.
    Singh JA
    Curr Opin Rheumatol; 2019 Mar; 31(2):159-166. PubMed ID: 30575598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Quality of treatment in gouty patients considering EULAR recommendations].
    Radak-Perović M; Zlatković-Svenda M
    Srp Arh Celok Lek; 2012; 140(11-12):717-21. PubMed ID: 23350244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allopurinol: insights from studies of dose-response relationships.
    Day RO; Kannangara DR; Stocker SL; Carland JE; Williams KM; Graham GG
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis.
    Yin R; Li L; Zhang G; Cui Y; Zhang L; Zhang Q; Fu T; Cao H; Li L; Gu Z
    BMJ Open; 2018 Apr; 8(4):e017542. PubMed ID: 29643150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
    Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
    Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.